ClinicalTrials.gg
TerminatedNCT05002569RELATIVITY-098Updated Jan 8, 2026Results posted

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

A Phase 3 interventional study of Nivolumab and Nivolumab + Relatlimab Fixed Dose Combination in Melanoma, sponsored by Bristol-Myers Squibb. Terminated at 184 sites in 25 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Why this study was terminated
Inability to meet protocol objectives

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,093
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 63 under way, 9 of them phase 3. Nivolumab · Melanoma.

Enrollment
3rd of 142
1,093 · median 50
Started
2021
with 9 others
Phase 3
19 of 142
2 open now
Registered
97th of 142
by date
Lead sponsor
23 of 142
Bristol-Myers Squibb

Among the 142 studies testing nivolumab in Melanoma, this one is the 3rd largest by enrollment, is one of 10 that started in 2021, is one of 19 in phase 3, and was the 97th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing nivolumab in Melanoma, or all of them as a file.
02

Study summary

The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • Melanoma
  • Relatlimab
  • Nivolumab
  • Opdivo
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have been diagnosed with either Stage IIIA (> 1 mm tumor in lymph node)/B/C/D or Stage IV melanoma by American Joint Committee on Cancer (AJCC) v8 and have confirmed melanoma that is completely surgically resected (free of disease) with negative margins in order to be eligible
  • Participants ≥ 18 years of age must have an (ECOG) performance status of ≤ 1. Adolescent participants between 12 and \< 18 years of age must have a Lansky/ performance score ≥ 80%
  • Complete resection must be performed within 90 days prior to randomization
  • All participants must have disease-free status documented by a complete physical examination within 14 days prior to randomization and imaging studies within 35 days prior to randomization
  • Tumor tissue must be provided for biomarker analyses

Exclusion criteria

Exclusion Criteria:

  • History of ocular melanoma
  • Untreated/unresected or
  • Active, known, or suspected disease
  • Participants with serious or uncontrolled medical disorder
  • Prior immunotherapy treatment for any prior : No prior immunotherapies are permitted
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 4 weeks prior to screening
  • History of myocarditis, regardless of etiology.

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,093 participants (actual)

Study arms

  • Experimental
    Arm A: Nivolumab Plus Relatlimab

    Combination

    Biological: Nivolumab + Relatlimab Fixed Dose Combination

  • Experimental
    Arm B: Nivolumab

    Monotherapy

    Biological: Nivolumab

Interventions

  • BiologicalNivolumab

    Specified dose on specified days

    Also known as: Opdivo, BMS-936558

  • BiologicalNivolumab + Relatlimab Fixed Dose Combination

    Drug pages: Nivolumab · Relatlimab

    Specified dose on specified days

    Also known as: BMS-986213, Opdualag

06

What researchers measure

Primary outcomes

  1. Recurrence Free Survival (RFS)

    RFS is defined as the time between the date of randomization and the first date of documented recurrence (local, regional, distant, new primary melanoma) or death due to any cause, whichever occurs first.

    Time frame: Approximately 27.5 Months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time between the date of randomization and the date of death due to any cause.

    Time frame: Approximately 27.5 Months

  2. Distant Metastasis Free Survival (DMFS)

    DMFS is defined as the time between the date of randomization and the date of first distant metastasis or date of death due to any cause, whichever occurs first.

    Time frame: Approximately 27.5 Months

  3. Progression Free Survival on Next-Line Systemic Therapy (PFS2)

    PFS2 defined as time from randomization to second recurrence/objective disease progression on next-line systemic therapy per investigator, or death from any cause, whichever occurs first.

    Time frame: Approximately 27.5 Months

  4. Number of Participants With Safety Related Events

    Safety related events encompass the following measures: Adverse events (AEs), Serious AEs, AEs leading to discontinuation, Drug-Related AEs and Deaths. An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment. An SAE is an AE which: * Results in death * Is life threatening * Requires hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Is an important medical event

    Time frame: Approximately 27.5 Months

  5. Number of Participants With Select AEs

    Select AEs will be reported as AEs per organ class. Organ classes which will be reported: * Gastrointestinal * Hepatic * Pulmonary * Renal * Skin * Hypersensitivity/Infusion reaction

    Time frame: Approximately 27.5 Months

  6. Number of Participants With Endocrine Related Immune Mediated AEs

    Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity.

    Time frame: Approximately 27.5 Months

  7. Number of Participants With Non-endocrine Related Immune Mediated AEs

    Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity.

    Time frame: Approximately 27.5 Months

  8. Laboratory Abnormalities for Specific Thyroid Tests

    Number of participants with laboratory abnormalities in specific thyroid tests.

    Time frame: Approximately 27.5 Months

07

Results

Posted Jan 8, 2026

Participant flow

Randomized
Participant flow — Randomized
MilestoneTreatment 1Treatment 2
Started547546
Completed543545
Not completed41
Withdrew: Withdrew consent30
Withdrew: No longer meets study criteria01
Withdrew: Ae unrelated to study drug10
Treatment Period
Participant flow — Treatment Period
MilestoneTreatment 1Treatment 2
Started543545
Completed283327
Not completed260218
Withdrew: Requested to discontinue265
Withdrew: Withdrew consent71
Withdrew: Study drug toxicity11464
Withdrew: Ae unrelated to study drug612
Withdrew: Disease recurrence102128
Withdrew: Other reasons47
Withdrew: Death11
Follow Up
Participant flow — Follow Up
MilestoneTreatment 1Treatment 2
Started543545
Completed15
Not completed542540
Withdrew: Death7869
Withdrew: Lost to follow-up33
Withdrew: Withdrew consent1716
Withdrew: Other reasons444452

Outcome measures

PrimaryRecurrence Free Survival (RFS)

RFS is defined as the time between the date of randomization and the first date of documented recurrence (local, regional, distant, new primary melanoma) or death due to any cause, whichever occurs first.

Time frame:
Approximately 27.5 Months
Reported as:
Median · Months
Recurrence Free Survival (RFS)
MonthsTreatment 1Treatment 2
Recurrence Free Survival (RFS)NA (0 to 37.7)33.84 (0 to 37.7)
SecondaryOverall Survival (OS)

OS is defined as the time between the date of randomization and the date of death due to any cause.

Time frame:
Approximately 27.5 Months
Reported as:
Median · Months
Overall Survival (OS)
MonthsTreatment 1Treatment 2
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryDistant Metastasis Free Survival (DMFS)

DMFS is defined as the time between the date of randomization and the date of first distant metastasis or date of death due to any cause, whichever occurs first.

Time frame:
Approximately 27.5 Months
Reported as:
Median · Months
Distant Metastasis Free Survival (DMFS)
MonthsTreatment 1Treatment 2
Distant Metastasis Free Survival (DMFS)NA (NA to NA)NA (33.84 to NA)
SecondaryProgression Free Survival on Next-Line Systemic Therapy (PFS2)

PFS2 defined as time from randomization to second recurrence/objective disease progression on next-line systemic therapy per investigator, or death from any cause, whichever occurs first.

Time frame:
Approximately 27.5 Months
Reported as:
Median · Months
Progression Free Survival on Next-Line Systemic Therapy (PFS2)
MonthsTreatment 1Treatment 2
Progression Free Survival on Next-Line Systemic Therapy (PFS2)NA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants With Safety Related Events

Safety related events encompass the following measures: Adverse events (AEs), Serious AEs, AEs leading to discontinuation, Drug-Related AEs and Deaths. An AE is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment that does not necessarily have a causal relationship with this treatment. An SAE is an AE which: * Results in death * Is life threatening * Requires hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Is an important medical event

Time frame:
Approximately 27.5 Months
Reported as:
Count of participants · Participants
Number of Participants With Safety Related Events
ParticipantsTreatment 1Treatment 2
AEs522520
Drug-Related AEs483438
Serious AEs13278
AEs leading to discontinuation10265
Deaths8376
SecondaryNumber of Participants With Select AEs

Select AEs will be reported as AEs per organ class. Organ classes which will be reported: * Gastrointestinal * Hepatic * Pulmonary * Renal * Skin * Hypersensitivity/Infusion reaction

Time frame:
Approximately 27.5 Months
Reported as:
Count of participants · Participants
Number of Participants With Select AEs
ParticipantsTreatment 1Treatment 2
Gastrointestinal115120
Hepatic10886
Pulmonary1113
Renal3321
Skin244240
Hypersensitivity/Infusion Reaction3726
SecondaryNumber of Participants With Endocrine Related Immune Mediated AEs

Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity.

Time frame:
Approximately 27.5 Months
Reported as:
Count of participants · Participants
Number of Participants With Endocrine Related Immune Mediated AEs
ParticipantsTreatment 1Treatment 2
Adrenal Insufficiency339
Hypothyroidism/Thyroiditis15893
Hypothyroidism15282
Thyroiditis1814
Diabetes Melitus118
Hyperthyroidism9656
Hypophysitis5113
SecondaryNumber of Participants With Non-endocrine Related Immune Mediated AEs

Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity.

Time frame:
Approximately 27.5 Months
Reported as:
Count of participants · Participants
Number of Participants With Non-endocrine Related Immune Mediated AEs
ParticipantsTreatment 1Treatment 2
Pneumonitis810
Diarrhea/colitis2821
Hepatitis2617
Nephritis and Renal Dysfunction33
Rash4940
Hypersensitivity122
SecondaryLaboratory Abnormalities for Specific Thyroid Tests

Number of participants with laboratory abnormalities in specific thyroid tests.

Time frame:
Approximately 27.5 Months
Reported as:
Count of participants · Participants
Laboratory Abnormalities for Specific Thyroid Tests
ParticipantsTreatment 1Treatment 2
TSH > ULN229159
TSH > ULN WITH TSH ≤ ULN AT BASELINE193124
TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN14874
TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES ≥ LLN168124
TSH > ULN WITH FT3/FT4 TEST MISSING5228
TSH < LLN198131
TSH <LLN WITH TSH ≥ LLN AT BASELINE180123
TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN11972
TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES ≤ ULN11785
TSH < LLN WITH FT3/FT4 TEST MISSING2719

Adverse events

Collected over Adverse Events, Serious Adverse Events and All-Cause mortality: Approximately 27.5 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment 186/547 (15.7%)174/543 (32%)489/543 (90.1%)
Treatment 276/546 (13.9%)121/545 (22.2%)473/545 (86.8%)
Most frequent serious events
Showing 10 of 234
Most frequent serious events
EventTreatment 1Treatment 2
HypophysitisEndocrine disorders13/5432/545
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/54312/545
MyositisMusculoskeletal and connective tissue disorders9/5430/545
MyocarditisCardiac disorders8/5431/545
Type 1 diabetes mellitusMetabolism and nutrition disorders6/5430/545
ColitisGastrointestinal disorders5/5431/545
DiarrhoeaGastrointestinal disorders5/5433/545
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/5435/545
Adrenal insufficiencyEndocrine disorders4/5431/545
Immune-mediated enterocolitisGastrointestinal disorders4/5433/545
Most frequent other events
Showing 10 of 33
Most frequent other events
EventTreatment 1Treatment 2
FatigueGeneral disorders161/543161/545
HypothyroidismEndocrine disorders150/54385/545
DiarrhoeaGastrointestinal disorders114/543117/545
PruritusSkin and subcutaneous tissue disorders112/543116/545
COVID-19Infections and infestations78/543110/545
ArthralgiaMusculoskeletal and connective tissue disorders100/543110/545
RashSkin and subcutaneous tissue disorders99/54386/545
HyperthyroidismEndocrine disorders96/54360/545
HeadacheNervous system disorders74/54394/545
NauseaGastrointestinal disorders86/54354/545

Baseline characteristics

All Randomized Participants

Age, Continuous
Age, Continuous(Years)Treatment 1Treatment 2Total
Mean57.3 ± 14.1657.6 ± 13.3457.4 ± 13.75
Sex: Female, Male
Sex: Female, Male(Participants)Treatment 1Treatment 2Total
Female220231451
Male327315642
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment 1Treatment 2Total
Hispanic or Latino463985
Not Hispanic or Latino280269549
Unknown or Not Reported221238459
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment 1Treatment 2Total
American Indian or Alaska Native000
Asian393776
Native Hawaiian or Other Pacific Islander000
Black or African American325
White491497988
More than one race000
Unknown or Not Reported141024
08

Study locations

184 sites
  • Local Institution - 0176
    Birmingham, Alabama 35249, United States
  • Local Institution - 0164
    Springdale, Arkansas 72762, United States
  • Local Institution - 0200
    Los Angeles, California 90025, United States
  • Local Institution - 0185
    Palo Alto, California 94304, United States
  • Local Institution - 0162
    San Francisco, California 94115, United States
  • Saint John's Cancer Institute
    Santa Monica, California 90404, United States
  • Local Institution - 0138
    Aurora, Colorado 80045, United States
  • Local Institution - 0166
    Washington D.C., District of Columbia 20007, United States
  • Local Institution - 0243
    Miami, Florida 33136, United States
  • Washington University School Of Medicine
    Miami, Florida 33136, United States
  • Local Institution - 0179
    Pensacola, Florida 32504, United States
  • Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center
    Tampa, Florida 33612, United States
  • Local Institution - 0191
    Atlanta, Georgia 30322, United States
  • Local Institution - 0148
    Atlanta, Georgia 30342, United States
  • Local Institution - 0202
    Chicago, Illinois 60611, United States
  • Local Institution - 0177
    Peoria, Illinois 61615, United States
  • Local Institution - 0223
    Fort Wayne, Indiana 46804, United States
  • University of Iowa-Holden Comprehensive Cancer Center
    Iowa City, Iowa 52242, United States
  • Local Institution - 0178
    Westwood, Kansas 66205, United States
  • Dana-Farber Cancer Institute-Melanoma
    Boston, Massachusetts 02215, United States
  • Local Institution - 0258
    Ann Arbor, Michigan 48109, United States
  • Local Institution
    Grand Rapids, Michigan 49503, United States
  • Local Institution - 0133
    Minneapolis, Minnesota 55407, United States
  • Local Institution - 0139
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0206
    Morristown, New Jersey 07960, United States
  • Local Institution - 0140
    New York, New York 10016, United States
  • Icahn School Of Medicine At Mount Sinai
    New York, New York 10029, United States
  • Local Institution - 0210
    New York, New York 10065, United States
  • Local Institution - 0130
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0145
    Durham, North Carolina 27710, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • Local Institution - 0141
    Cleveland, Ohio 44195, United States
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C
    Columbus, Ohio 43210, United States
  • Local Institution - 0267
    Allentown, Pennsylvania 18103, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Local Institution - 0125
    Pittsburgh, Pennsylvania 15232, United States
  • Local Institution - 0171
    Charleston, South Carolina 29425, United States
  • Local Institution - 0147
    Germantown, Tennessee 38138, United States
  • Local Institution - 0183
    Nashville, Tennessee 37232, United States
  • Local Institution - 0146
    Austin, Texas 78731, United States
  • Local Institution - 0163
    Dallas, Texas 75246, United States
  • Local Institution - 0172
    Houston, Texas 77030, United States
  • Local Institution - 0137
    Fairfax, Virginia 22031, United States
  • Local Institution - 0003
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ABP, Argentina
  • Local Institution - 0005
    Buenos Aires, Distrito Federal 1426, Argentina
  • Local Institution - 0001
    CABA, Distrito Federal C1430, Argentina
  • Local Institution - 0002
    Ciudad de Buenos Aires, Distrito Federal C1121ABE, Argentina
  • Local Institution - 0004
    Córdoba, X5002HWE, Argentina
  • Local Institution - 0030
    Waratah, New South Wales 2298, Australia
  • Local Institution - 0252
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0032
    Wollstonecraft, New South Wales 2065, Australia
  • Local Institution - 0254
    Tiwi, Northern Territory 0810, Australia
  • Local Institution - 0028
    Brisbane, Queensland 4102, Australia
  • Local Institution - 0027
    Southport, Queensland 4215, Australia
  • Local Institution - 0250
    Woodville, South Australia 5011, Australia
  • Local Institution - 0035
    Ballarat, Victoria 3350, Australia
  • Local Institution - 0253
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0031
    Melbourne, Victoria 3000, Australia
  • Local Institution - 0251
    Murdoch, Western Australia 6150, Australia
  • Local Institution - 0029
    Perth, Western Australia 6009, Australia
  • Local Institution - 0082
    Graz, Styria 8036, Austria
  • Local Institution - 0086
    Salzburg, 5020, Austria
  • Local Institution - 0084
    Vienna, 1090, Austria
  • Local Institution - 0110
    Brussels, 1090, Belgium
  • Local Institution - 0105
    Brussels, 1200, Belgium
  • Local Institution - 0109
    Liège, 4000, Belgium
  • Local Institution - 0106
    Wilrijk, 2610, Belgium
  • Local Institution - 0072
    Fortaleza, Ceará 60135237, Brazil
  • Local Institution - 0068
    Vitória, Espírito Santo 29055450, Brazil
  • Local Institution - 0071
    Salvador, Estado de Bahia 40170-070, Brazil
  • Local Institution - 0047
    Belo Horizonte, Minas Gerais 30130-090, Brazil
  • Local Institution - 0056
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Local Institution - 0257
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
  • Local Institution - 0049
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Local Institution - 0048
    Santa Cruz do Sul, Rio Grande do Sul 96830-180, Brazil
  • Local Institution - 0070
    Barretos, São Paulo 14784400, Brazil
  • Local Institution - 0058
    Rio de Janeiro, 20220-410, Brazil
  • Local Institution - 0155
    Edmonton, Alberta T6X 1E8, Canada
  • Local Institution - 0175
    Vancouver, British Columbia V5Z 4E6, Canada
  • Local Institution - 0197
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Local Institution - 0159
    Montreal, Quebec H2X 1P1, Canada
  • Local Institution - 0158
    Montreal, Quebec H3T 1E2, Canada
  • Local Institution - 0160
    Québec, Quebec G1J 1Z4, Canada
  • Local Institution - 0198
    Sherbrooke, Quebec J1H 5N4, Canada
  • Local Institution - 0013
    Santiago, Santiago Metropolitan 7510032, Chile
  • Local Institution - 0006
    Santiago, Santiago Metropolitan 8420383, Chile
  • Local Institution - 0014
    Santiago, Santiago Metropolitan, Chile
  • Local Institution - 0221
    Hefei, Anhui 230022, China
  • Local Institution - 0259
    Beijing, Beijing Municipality 100034, China
  • Local Institution - 0261
    Beijing, Beijing Municipality 100035, China
  • Local Institution - 0214
    Beijing, Beijing Municipality 100142, China
  • Local Institution - 0241
    Chongqing, Chongqing Municipality 400030, China
  • Local Institution - 0245
    Fuzhou, Fujian 350014, China
  • Local Institution - 0217
    Guangzhou, Guangdong 510060, China
  • Local Institution - 0226
    Zhengzhou, Henan 450001, China
  • Local Institution - 0237
    Wuhan, Hubei 430022, China
  • Local Institution - 0239
    Wuhan, Hubei 430030, China
  • Local Institution - 0234
    Changsha Shi, Hunan 410013, China
  • Local Institution - 0215
    Nanjing, Jiangsu 210000, China
  • Local Institution - 0225
    Nanjing, Jiangsu 210029, China

Showing the first 100 of 184 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Long GV, Garnett-Benson C, Dolfi S, Ascierto PA, Guo J, Tarhini AA, Chandra S, Munoz-Couselo E, Del Vecchio M, de Melo AC, Callahan M, Gogas H, Dummer R, Schadendorf D, Koelblinger P, Quereux G, Thomas I, Yu JX, Fisher A, Wang B, Djidel P, Chouzy A, Semaan M, Chen B, Cheong AMY, Tawbi HA. Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial. Nat Med. 2025 Dec;31(12):4301-4309. doi: 10.1038/s41591-025-04032-8. Epub 2025 Oct 18. PubMed 41109920 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Dec 2024, 37 months.

Results were first posted in Jan 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2021
First posted
Aug 12, 2021
StartActual
Oct 19, 2021
Primary completionActual
Dec 16, 2024
CompletionActual
Apr 2, 2025
Results first posted
Jan 8, 2026
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05002569
Responsible party
Sponsor
First posted
Aug 12, 2021
Start date
Oct 19, 2021
Primary completion
Dec 16, 2024
Completion
Apr 2, 2025
Results posted
Jan 8, 2026
Last update
Jan 8, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Relatlimab

Start the discussion